Pilot validation of an individualised pharmacokinetic algorithm for protamine dosing after systemic heparinisation for cardiopulmonary bypass

Rosin MW Holt D . Heparin dose and postoperative bleeding in patients undergoing cardiopulmonary bypass. J Extra Corpor Technol 2013; 45: 228–234.

Bouraghda A Gillois P Albaladejo P . Les différentes alternatives d’anticoagulation au couple héparine/protamine en chirurgie cardiaque sous circulation extra-corporelle. Can J Anesth 2015; 62: 518–528.

Holland L . Adverse reactions to protamine sulfate following cardiac surgery. Clin Cardiol 1984; 162: 157–162.

Khan NU Wayne CK Barker J Strang T . The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol 2010; 27: 624–627.

Mochizuki T Olson PJ Szlam F Ramsay JG Levy JH . Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87: 781–785.

Ni Ainle F Preston RJS Jenkins PV et al . Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood 2009; 114: 1658–1665.

Noui N Zogheib E Walczak K et al . Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion 2012; 27: 214–220.

Shore-Lesserson L Reich DL DePerio M . Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth 1998; 45: 10–18.

Davidsson FO Johagen D Appelblad M Svenmarker S . Reversal of heparin after cardiac surgery: protamine titration using a statistical model. J Cardiothorac Vasc Anesth 2015; 29: 710–714.

Meesters MI Veerhoek D de Jong JR Boer C . A pharmacokinetic model for protamine dosing after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2016; 30; 1190–1195.

Jia Z Tian G Ren Y Sun Z Lu W Hou X . Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery. J Transl Med 2015; 13: 45.

Kjellberg G Sartipy U van der Linden J Nissborg E Lindvall G . An adjusted calculation model allows for reduced protamine doses without increasing blood loss in cardiac surgery. Thorac Cardiovasc Surg 2016; 64: 487–493.

Bendetowicz A V Béguin S Caplain H Hemker HC . Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin–a three way cross over study in human volunteers. Thromb Haemost 1994; 71: 305–313.

Estes JW . Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980; 5: 204–220.

Brunton L Chabner B Knollman B . Goodman & Gilman’s The Pharmacological Basis of Therapeutics (12th Edition). New York: McGraw Hill; 2011. p. 1937.

DeLaria GA Tyner JJ Hayes CL Armstrong BW . Heparin-protamine mismatch. A controllable factor in bleeding after open heart surgery. Arch Surg 1994; 129: 944–950; discussion 950–951.

Ferraris VA Brown JR Despotis GJ et al . Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines. Ann Thorac Surg 2011; 91: 944–982.

Meesters MI Veerhoek D de Lange F et al . Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. A randomised clinical trial. Thromb Haemost 2016; 116: 251–261.

Wright SJ Murray WB Hampton WA Hargovan H . Calculating the protamine-heparin reversal ratio: a pilot study investigating a new method. J Cardiothorac Vasc Anesth 1993; 7: 416–421.

Koster A Börgermann J Gummert J Rudloff M Zittermann A Schirmer U . Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass. Clin Appl Thromb 2014; 20: 290–295.

Despotis GJ Summerfield AL Joist JH et al . Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108: 1076–1082.

Ranucci M Isgrò G Cazzaniga A et al . Different patterns of heparin resistance: therapeutic implications. Perfusion 2002; 17: 199–204.

Despotis GJ Joist JH Hogue CW et al . More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76: 902–908.

Despotis GJ Joist JH Hogue CW et al . The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110: 46–54.

Jobes DR Aitken GL Shaffer GW . Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995; 110: 36–45.

Slight RD Buell R Nzewi OC McClelland DBL Mankad PS . A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2008; 22: 47–52.

Garvin S FitzGerald DC Despotis G Shekar P Body SC . Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg 2010; 111: 849–855.

de Jong JR Boer C Davidsson FÖ et al . Calculating the protamine dose necessary to neutralize heparin in all patients under all circumstances. J Cardiothorac Vasc Anesth 2016; 30: e6–7.

Papachristofi O Sharples LD Mackay JH Nashef SAM Fletcher SN Klein AA . The contribution of the anaesthetist to risk-adjusted mortality after cardiac surgery. Anaesthesia 2016; 71: 138–146.

Alston RP . Asked and answered: is the mortality associated with cardiac surgery related to the anaesthetist and should it be used to measure anaesthetic performance? Anaesthesia 2016; 71: 123–137.

Kaplan JA . Plasma heparin activity and antagonism during cardiopulmonary bypass with hypothermia. Anesth Analg 1977; 56: 564–569.

Ereth MH Fisher BR Cook DJ Nuttall GA Orszulak TA Oliver WC . Normothermic cardiopulmonary bypass increases heparin requirements necessary to maintain anticoagulation. J Clin Monit Comput 1998; 14: 323–327.

Iyer YL Hayward P McNicol L Weinberg L . The effects on coagulation of the reinfusion of unprocessed residual blood from the cardiopulmonary bypass. BMC Res Notes 2016; 9: 61–67.

Duara R Misra M Bhuyan RR Sarma PS Jayakumar K . Does transfusion of residual cardiopulmonary bypass circuit blood increase postoperative bleeding? A prospective randomized study in patients undergoing on pump cardiopulmonary bypass. Asian J Transfus Sci 2008; 2: 51-55.

Singh G Gayler M Wyatt R Spyt T . Clinical significance of heparin in the residual pump oxygenator blood, reinfused postoperatively after cardiopulmonary bypass. Perfusion 1994; 9: 271–275.

Watanabe J Hori K Iwamoto K Ozeki S . Disposition of tritium-labelled heparin in rats. J Pharmacobiodynamics 1982; 5: 627–637.

de Swart C Nijmeyer B Roelofs J Sixma J . Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60: 1251–1259.

Butterworth J Lin YA Prielipp R Bennett J James R . The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg 2002; 94: 514–522

Ichikawa J Kodaka M Nishiyama K Hirasaki Y Ozaki M Komori M . Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 2014; 28: 1003–1007.

Teoh KHT Young E Blackall MH Roberts RS Hirsh J . Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg 2004; 128: 211–219.